VFMCRP announces positive results of phase-III clinical trial of Velphoro® in China
Retrieved on:
Friday, April 30, 2021
Health, Clinical trials, Research, Pharmaceutical, Science, Biotechnology, Chemistry, Physical sciences, Chemical elements, Phosphate binders, Dietary minerals, Vifor Pharma, Sevelamer, Sucroferric oxyhydroxide, Phosphorus, XC2, Calcium, the PA-CL-CHINA-01 study, Velphoro®, THE PA-CL-CHINA-01 STUDY, VELPHORO®
The study met its primary endpoint demonstrating non-inferiority versus sevelamer carbonate in the change from baseline in serum phosphorus levels at week 12.\nDr.
Key Points:
- The study met its primary endpoint demonstrating non-inferiority versus sevelamer carbonate in the change from baseline in serum phosphorus levels at week 12.\nDr.
- In 2020, Velphoro\xc2\xae became a global leader by value in the calcium-free phosphate binder market2.\n1 Zhang et al.
- Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives.
- Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210429005950/en/\n'